Veena Rao, PhD
Research ScientistCards
About
Research
Publications
2026
Blood aldosterone concentrations and effects of mineralocorticoid receptor antagonists in heart failure
Rao V, Ivey-Miranda J, Cox Z, Wilson F, Petrie M, Sarnak M, Wilcox C, Pitt B, McCallum W, Testani J. Blood aldosterone concentrations and effects of mineralocorticoid receptor antagonists in heart failure. European Heart Journal 2026, ehag440. PMID: 42301739, DOI: 10.1093/eurheartj/ehag440.Peer-Reviewed Original ResearchMineralocorticoid receptor antagonistsMineralocorticoid receptor antagonist useMineralocorticoid receptor antagonist initiationAldosterone concentrationClinical outcomesMR activationHeart failureReceptor antagonistEffects of mineralocorticoid receptor antagonistsPooled cohortMineralocorticoid receptor antagonist therapyAssociated with worse clinical outcomesPooled cohort analysisBlood aldosterone concentrationPlasma aldosterone concentrationHypothesis-generating findingsSodium-to-potassium ratioUrine sodium-to-potassium ratioHF medicationsAldosterone productionHF cohortAldosteroneCohort analysisPatientsCohortFluid Management of Acute Heart Failure With the Reprieve System The Randomized Controlled FASTR Trial
Udelson J, Javaheri A, Fudim M, Damman K, Biegus J, Afzal A, Amin A, Bensimhon D, Bischof J, Chung E, Gottlieb R, Mahler S, Moreno J, Ponikowski P, Rao V, Cox Z, Ivey-Miranda J, Collins S, Testani J. Fluid Management of Acute Heart Failure With the Reprieve System The Randomized Controlled FASTR Trial. JACC Heart Failure 2026, 103062. PMID: 42068320, DOI: 10.1016/j.jchf.2026.103062.Peer-Reviewed Original ResearchOptimal diuretic therapyAcute heart failureCreatinine levelsSafety endpointsHeart failureFluid managementManagement of acute heart failureComposite of dialysisDoubling of creatinine levelSerum creatinine levelsPrimary safety endpointSevere electrolyte abnormalitiesCardio-renal dysfunctionNet fluid lossPilot trialDiuretic therapyRandomized pilot trialEfficacy endpointHypertensive emergenciesElectrolyte abnormalitiesTherapy durationHospitalized patientsNatriuresisRandomized treatmentRapid decongestion
2025
Authors' Reply: Refining the Map of Diuretic Resistance in Acute Heart Failure
Cox Z, Rao V, Ivey-Miranda J, Testani J. Authors' Reply: Refining the Map of Diuretic Resistance in Acute Heart Failure. Journal Of The American Society Of Nephrology 2025, 37: 1104-1104. PMID: 41563823, PMCID: PMC13143457, DOI: 10.1681/asn.0000000948.Commentaries, Editorials and LettersLoop Diuretic Dose Intensification versus Adjuvant Thiazide for Diuretic Resistance in Acute Heart Failure
Rao V, Cox Z, Ivey-Miranda J, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Turner J, Wilson F, Shilpak M, Estrella M, Welling P, Wilcox C, Ellison D, Forbush B, Testani J. Loop Diuretic Dose Intensification versus Adjuvant Thiazide for Diuretic Resistance in Acute Heart Failure. Journal Of The American Society Of Nephrology 2025, 37: 533-544. PMID: 40938670, PMCID: PMC12935386, DOI: 10.1681/asn.0000000887.Peer-Reviewed Original ResearchFractional excretion of lithiumDose intensificationDiuretic resistanceDiuretic responseFractional excretionHeart failurePrimary outcomeResistance mechanismsLoop diuretic resistanceAcute heart failureExcretion of lithiumLoop of HenleDiuretic strategyRandomized Controlled TrialsSite of actionPrimary trial outcomeOptimal therapyThiazideScreening visitNatriuresisControlled TrialsPatientsInduced increaseExploratory analysisTherapyProteins associated with rehospitalization, mortality and diuretic resistance in acutely decompensated heart failure
Hubbell K, Rao V, Scherzer R, Shlipak M, Ivery‐Miranda J, Bansal N, Cox Z, Testani J, Estrella M. Proteins associated with rehospitalization, mortality and diuretic resistance in acutely decompensated heart failure. ESC Heart Failure 2025, 12: 3296-3305. PMID: 40504107, PMCID: PMC12450773, DOI: 10.1002/ehf2.15342.Peer-Reviewed Original ResearchAcute decompensated heart failureDecompensated heart failureDiuretic responseHeart failureHF rehospitalizationRisk of HF rehospitalizationBiomarker modelAssociated with poor outcomesAssociated with decreased riskAssociated with increased riskAssociated with cardiometabolic diseasesAssociated with mortalityAssociated with rehospitalizationDiuretic resistanceMedian ageResistance cohortClinical factorsPoor outcomeSociodemographic/lifestyle factorsPrognostic toolCombined biomarkersCardiometabolic diseasesPatientsAmbulatory settingMortality riskEvaluation of the Natriuretic Response Prediction Equation Using a Race-free Estimated Glomerular Filtration Rate Equation
Cox Z, Rao V, Wrenn J, Collins S, Testani J, Ivey-Miranda J. Evaluation of the Natriuretic Response Prediction Equation Using a Race-free Estimated Glomerular Filtration Rate Equation. Journal Of Cardiac Failure 2025, 31: 1582-1586. PMID: 40441408, DOI: 10.1016/j.cardfail.2025.05.013.Peer-Reviewed Original ResearchNatriuretic response prediction equation for use with oral diuretics in heart failure
Ivey-Miranda J, Rao V, Cox Z, Moreno-Villagomez J, Mastache D, Collins S, Testani J. Natriuretic response prediction equation for use with oral diuretics in heart failure. European Heart Journal 2025, 46: 2410-2418. PMID: 40272149, PMCID: PMC12208776, DOI: 10.1093/eurheartj/ehaf268.Peer-Reviewed Original ResearchConceptsMechanisms of diuretic resistanceArea under the curvePoor diuretic responseDiuretic responseHeart failureDiuretic doseOral diureticsNatriuretic responseHF patient cohortsLoop diuretic doseOral loop diureticsUrine samplesTimed urine collectionsOral loopDiuretic resistanceLoop diureticsDiuretic administrationUrine volumePatient cohortUrine collectionStudy visitsDiureticsPatientsUrineDoseReprieve System for the Treatment of Patients With Acute Decompensated Heart Failure
Ivey-Miranda J, Rao V, Shaburishvili T, Verulava I, Khabeishvili N, Petrie M, Butler J, Nunez J, Biegus J, Ponikowski P, Damman K, Collins S, Testani J, Cox Z. Reprieve System for the Treatment of Patients With Acute Decompensated Heart Failure. Journal Of Cardiac Failure 2025, 31: 1085-1089. PMID: 39947422, DOI: 10.1016/j.cardfail.2025.02.002.Peer-Reviewed Original Research
2024
Development of a Novel Intraperitoneal Icodextrin/Dextrose Solution for Enhanced Sodium Removal
Asher J, Ivey-Miranda J, Maulion C, Cox Z, Borges-Vela J, Mendoza-Zavala G, Cigarroa-Lopez J, Silva-Rueda R, Revilla-Monsalve C, Moreno-Villagomez J, Ramos-Mastache D, Goedje O, Crosbie I, McIntyre C, Finkelstein F, Turner J, Testani J, Rao V. Development of a Novel Intraperitoneal Icodextrin/Dextrose Solution for Enhanced Sodium Removal. Kidney Medicine 2024, 7: 100938. PMID: 39790231, PMCID: PMC11714391, DOI: 10.1016/j.xkme.2024.100938.Peer-Reviewed Original ResearchPD solutionsPeritoneal dialysisSodium removalIcodextrin PD solutionExposure of miceLong-term safetyClearance of uremic toxinsChronic therapyEdematous disordersStructural tissue changesAdverse eventsRemoval therapyEfficacy resultsHeart failureEvaluate safetyNet ultrafiltrationUremic toxin clearanceAnimal modelsIcodextrinKidney failureUremic toxinsTissue changesAscending concentrationsEfficient ultrafiltrationEfficacyMechanistic Differences between Torsemide and Furosemide
Rao V, Cox Z, Ivey-Miranda J, Neville D, Balkcom N, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Tang W, Collins S, Velazquez E, Mentz R, Wilson F, Turner J, Wilcox C, Ellison D, Fang J, Testani J. Mechanistic Differences between Torsemide and Furosemide. Journal Of The American Society Of Nephrology 2024, 36: 99-107. PMID: 39196651, PMCID: PMC11706557, DOI: 10.1681/asn.0000000000000481.Peer-Reviewed Original ResearchTorsemide groupDiuretic doseTubular site of actionHigher diuretic dosesDose of furosemideProportion of dosesOral furosemideSite of actionPrescribed doseNeurohormonal activationMechanistic substudyClinical outcomesPharmacodynamic advantagesKidney dysfunctionPharmacodynamic parametersKidney functionRandomized trialsNatriuresisTubular sitesFurosemideTorsemideDoseTRANSFORM-HFPlasma volumeBody weight
Clinical Trials
Current Trials
Mechanisms of Diuretic Resistance in Heart Failure (MsDR)
IRB ID2000032328RoleSub InvestigatorPrimary Completion Date03/31/2028Recruiting ParticipantsGenderBothAge18+ years
Get In Touch
Contacts
Mailing Address
Yale School of Medicine
135 College St
New Haven, CT 06510
United States